AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06267209 — intervention group
Intervention type: OTHER
Intervention: Observational group
Description: After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors.
Study NCT04719611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
Study NCT05575102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Football
Description: Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games.
Study NCT04755647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Releasing Solution
Description: Active antimicrobial
Study NCT04755647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution, hypotonic
Description: Placebo
Study NCT06289829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: remifentanil of the assigned dose
Description: Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
Study NCT06289829 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu Auragain for airway management
Description: Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
Study NCT06413940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofunctional Therapy
Description: Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes
Study NCT06413940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.
Study NCT06413940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise intensity :40%-60% HRmax , 3-5 days/week
Study NCT05376930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Amg
Description: DWP16001 Amg, Tablets, Orally, Once daily
Study NCT05918211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Active drug
Study NCT05918211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT05849766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Farxiga®
Description: Dapagliflozin 10 mg once daily
Study NCT04134026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIF-PHI
Description: Drug will be dosed orally three times a week.
Study NCT04134026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: The drug will be dispensed per the package insert or the country-specific product labeling.
Study NCT04938986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMMUNOSCORE®
Description: recommendation for patient care according to the result of the IMMUNOSCORE®
Study NCT06368557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoolMinds: Internet-based cognitive behavioral therapy (iCBT)
Description: The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
Study NCT05849766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®
Description: Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
Study NCT05858593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality curriculum
Description: Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
Study NCT05858593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Virtual reality curriculum
Description: Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
Study NCT05982015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
Study NCT05982015 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine 1
Description: quadrivalent seasonal influenza vaccine
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.1
Description: Sterile liquid for injection
Study NCT05097469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide laser
Description: 3 consecutive sessions of carbon dioxide laser treatment
Study NCT05097469 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser treatment
Description: 3 consecutive sessions of sham laser treatment
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.2
Description: Sterile liquid for injection
Study NCT05593822 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary percutaneous intervention
Description: percutaneous catheterization through peripheral arteries to coronary arteries
Study NCT06293443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lower extremity unilateral amputee
Description: To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083.3
Description: Sterile liquid for injection
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Influenza Vaccine 1
Description: Sterile liquid for injection
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational COVID-19 Vaccine 1
Description: Sterile liquid for injection
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine 1
Description: Sterile liquid for injection
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Influenza Vaccine 2
Description: Sterile liquid for injection
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine 2
Description: quadrivalent seasonal influenza vaccine
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1083
Description: Sterile liquid for injection
Study NCT05653193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care
Description: Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
Study NCT05653193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antifungals as standard of care
Description: Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
Study NCT06405958 — intervention group
Intervention type: OTHER
Intervention: gut microbiome
Description: Obtaining new gut microbiome data in organ transplantation
Study NCT05915221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMS
Description: Receive SMS
Study NCT04175704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: UB-221
Description: Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
Study NCT06046495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1004
Description: PLB1004 will be orally self-administered by the patient as a mono-therapy.
Study NCT05009316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Online-based questionnaires
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational COVID-19 Vaccine 2
Description: Sterile liquid for injection
Study NCT05827926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine 2
Description: Sterile liquid for injection
Study NCT05458297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion
Study NCT05458297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral tablet
Study NCT05932641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Cohort 1)
Description: Single dose of AZD3152 300 mg IM on Visit 2 Day 1
Study NCT05932641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 1)
Description: Single dose of Placebo IM on Visit 2 Day 1
Study NCT05932641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Cohort 2)
Description: Single dose of AZD3152 600 mg IM on Visit 2 Day 1
Study NCT05932641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 2)
Description: Single dose of Placebo IM on Visit 2 Day 1
Study NCT05932641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD3152 (Cohort 3)
Description: Single dose of AZD3152 1200 mg IV on Visit 2 Day 1
Study NCT05932641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Cohort 3)
Description: Single dose of Placebo IM on Visit 2 Day 1
Study NCT05690581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM369
Description: Specified dose on specified days.
Study NCT03806751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [O-15]Water
Description: All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Study NCT05631327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP341
Description: JZP341 will be administered as a single, intravenous infusion over 2 hours.
Study NCT03806751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
Study NCT05927727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound and biyopsy
Description: Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
Study NCT06121557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for harvesting tumor-draining lymph nodes
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
Study NCT06121557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study NCT06121557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study NCT06121557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
Study NCT06121557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
Study NCT06121557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT06121557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic drug, ADC or PARP inhibitor
Description: Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
Study NCT04437563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HERMES
Description: Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
Study NCT04719338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .
Description: samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
Study NCT06502470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ellacor® Micro-Coring procedure
Description: ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Study NCT05401357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - Bimatoprost 0.01% Ophthalmic Solution
Description: Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
Study NCT05401357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Description: Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
Study NCT06002607 — intervention group
Intervention type: OTHER
Intervention: Antibiotic duration
Description: The patient will be enrolled in a 48-hour course of antibiotics.
Study NCT06002607 — intervention group
Intervention type: OTHER
Intervention: Antibiotic duration
Description: The patient will be enrolled in a 7 day course of antibiotics.
Study NCT05987293 — intervention group
Intervention type: DEVICE
Intervention: Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.
Description: A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
Study NCT05383521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole 56
Description: Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Study NCT05383521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole 42
Description: Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
Study NCT05274880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393
Description: PO, QD
Study NCT04968119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in telehealth exercise sessions
Study NCT04968119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participate in telehealth exercise sessions
Study NCT04968119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04968119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06639425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei LC19 supplementation
Description: Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
Study NCT06639425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotic milk powder
Description: Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
Study NCT06483282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Study NCT06483282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.
Study NCT06483282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
Study NCT04968119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04968119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies